Literature DB >> 2910511

Failure of response to ifosfamide in squamous cell bronchogenic carcinoma.

J Banks, E G Anderson, A P Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2910511     DOI： 10.1007/BF00273534

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  6 in total

1.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.

Authors:  E A GEHAN
Journal:  J Chronic Dis       Date:  1961-04

2.  Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.

Authors:  J J Costanzi; R Gagliano; D Loukas; F J Panettiere; J A Hokanson
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

Review 3.  Ifosfamide--pharmacology, safety and therapeutic potential.

Authors:  W P Brade; K Herdrich; M Varini
Journal:  Cancer Treat Rev       Date:  1985-03       Impact factor: 12.111

4.  Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.

Authors:  L R Morgan; L E Posey; J Rainey; J Bickers; D Ryan; R Vial; E W Hull
Journal:  Cancer Treat Rep       Date:  1981 Jul-Aug

5.  Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.

Authors:  E F Harrison; J E Hawke; H L Hunter; J J Costanzi; L R Morgan; D Plotkin; W G Tucker; P M Worrall
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

6.  Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.

Authors:  J J Costanzi; L R Morgan; J Hokanson
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929
  6 in total
  1 in total

1.  Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; D K Hossfeld; R Zschaber; W Achterrath; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.